OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Aptamer-Based Targeted Protein Degradation
Yuan Liu, Xu Qian, Chunyan Ran, et al.
ACS Nano (2023) Vol. 17, Iss. 7, pp. 6150-6164
Open Access | Times Cited: 47

Showing 1-25 of 47 citing articles:

Chemically Modified Platforms for Better RNA Therapeutics
Yesi Shi, Xueyan Zhen, Yiming Zhang, et al.
Chemical Reviews (2024) Vol. 124, Iss. 3, pp. 929-1033
Closed Access | Times Cited: 44

Nanotechnology Reprogramming Metabolism for Enhanced Tumor Immunotherapy
Yangkai Zhou, Jing Yuan, Ke Xu, et al.
ACS Nano (2024) Vol. 18, Iss. 3, pp. 1846-1864
Closed Access | Times Cited: 21

Nano-PROTACs: state of the art and perspectives
Jie Zhong, Ruiqi Zhao, Yuji Wang, et al.
Nanoscale (2024) Vol. 16, Iss. 9, pp. 4378-4391
Closed Access | Times Cited: 18

Expanding the horizons of targeted protein degradation: A non-small molecule perspective
Xiaowei Huang, Fengbo Wu, Jing Ye, et al.
Acta Pharmaceutica Sinica B (2024) Vol. 14, Iss. 6, pp. 2402-2427
Open Access | Times Cited: 16

Aptamer-based assembly systems for SARS-CoV-2 detection and therapeutics
Yuhang Dong, Jingping Wang, Ling Chen, et al.
Chemical Society Reviews (2024) Vol. 53, Iss. 13, pp. 6830-6859
Closed Access | Times Cited: 15

Aptamers: Promising Reagents in Biomedicine Application
Hongxin Zhou, Yuhuan Li, Weizhong Wu
Advanced Biology (2024) Vol. 8, Iss. 6
Closed Access | Times Cited: 14

What influences the activity of Degrader−Antibody conjugates (DACs)
Yaolin Guo, Xiaoxue Li, Yang Xie, et al.
European Journal of Medicinal Chemistry (2024) Vol. 268, pp. 116216-116216
Closed Access | Times Cited: 9

Targeted protein degradation in drug development: Recent advances and future challenges
Jian H. Song, Mingzheng Hu, Jun Zhou, et al.
European Journal of Medicinal Chemistry (2023) Vol. 261, pp. 115839-115839
Closed Access | Times Cited: 17

Proteolysis-targeting drug delivery system (ProDDS): integrating targeted protein degradation concepts into formulation design
Yu Chen, Fengyuan Liu, Samira Pal, et al.
Chemical Society Reviews (2024) Vol. 53, Iss. 19, pp. 9582-9608
Closed Access | Times Cited: 6

Application of PROTACs in target identification and validation
Yang Liu, Jing Liang, Rui Zhu, et al.
Acta Materia Medica (2024) Vol. 3, Iss. 1
Open Access | Times Cited: 5

Progress of proteolysis-targeting chimeras (PROTACs) delivery system in tumor treatment
Lianlian Fan, Weifang Tong, Anhui Wei, et al.
International Journal of Biological Macromolecules (2024) Vol. 275, pp. 133680-133680
Open Access | Times Cited: 5

Selection of biofilm-inhibiting ssDNA aptamers against antibiotic-resistant Edwardsiella tarda by inhibition-SELEX and interaction with their binding proteins
Yunting Fan, Jiang Zheng, Ying Tan, et al.
International Journal of Biological Macromolecules (2025), pp. 140041-140041
Closed Access

Development of a nano-targeting chimera for the degradation of membrane and cytoplasmic proteins
Peipei Jin, Zhaozheng Chen, Ju Zhang, et al.
Acta Biomaterialia (2025)
Closed Access

Recent Advances in Propranolol Hydrochloride Formulations for the Treatment of Infantile Hemangiomas
Lin Ren, Xiaowen Xu, Xianbin Liu, et al.
Drug Design Development and Therapy (2025) Vol. Volume 19, pp. 1163-1183
Open Access

Multivalent DNA lysosome-targeting chimaera for targeted protein degradation and inhibition of c-Met signaling pathways
Xinhuan Chen, Mengmeng Ji, Xue Bai, et al.
Chemical Engineering Journal (2025), pp. 161974-161974
Closed Access

Integrating Proteolysis‐Targeting Chimeras (PROTACs) with Delivery Systems for More Efficient and Precise Targeted Protein Degradation
Jiachan Lin, Zirui Chen, Dan Zhang, et al.
Macromolecular Rapid Communications (2025)
Closed Access

Utilizing aptamers in targeted protein degradation strategies for disease therapy
Li Lin, Songbo Xie, Jun Zhou, et al.
The Journal of Pathology (2025)
Closed Access

Multistage Self-Assembled Nanomaterials for Cancer Immunotherapy
Lamei Guo, Jinjun Yang, Hao Wang, et al.
Molecules (2023) Vol. 28, Iss. 23, pp. 7750-7750
Open Access | Times Cited: 9

Securing LYTAC with Logic‐Identification System for Cancer Cell‐Selective Membrane Protein Degradation
Yanyun Fang, Yue Zhang, Shiyi Bi, et al.
Small (2024) Vol. 20, Iss. 30
Closed Access | Times Cited: 3

Advances in Aptamer-Based Biosensors for the Detection of Foodborne Mycotoxins
Yangyang Li, Dan Zhang, Xiaoyuan Zeng, et al.
Molecules (2024) Vol. 29, Iss. 16, pp. 3974-3974
Open Access | Times Cited: 3

Nanomedicine-induced programmed cell death in cancer therapy: mechanisms and perspectives
Luobin Lin, He Wanxin, Yingxin Guo, et al.
Cell Death Discovery (2024) Vol. 10, Iss. 1
Open Access | Times Cited: 3

CRBN‐PROTACs in Cancer Therapy: From Mechanistic Insights to Clinical Applications
Riya Thapa, Asif Ahmad Bhat, Gaurav Gupta, et al.
Chemical Biology & Drug Design (2024) Vol. 104, Iss. 5
Open Access | Times Cited: 3

Page 1 - Next Page

Scroll to top